SARS ‐CoV‐2 targeting by RNAi and host complement inhibition: A two‐pronged subterfuge for COVID‐19 treatment

ConclusionSARS-CoV-2 specific RNAi in conjunction with systemic delivery of compstatin will be an effective two-pronged strategy to combat local and systemic immune responses in both symptomatic and asymptomatic COVID-19 patients.

Source: Immunity, Inflammation and Disease - October 13, 2021 Category: Allergy & Immunology Authors: Raza Ali Naqvi, Deepak Shukla, Afsar R. Naqvi Tags: REVIEW ARTICLE Source Type: research